Comprehensive Vital Organ Biomarkers Analysis of the Consciousness Energy Healing Based Novel Test Formulation Using Various Cell-lines
Organ Health
<p style="text-align:justify;">The aim was to study the effect of the Consciousness Energy Treated test formulation on vital organ functions viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Alan Joseph Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was found as safe and non-toxic in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Energy Treated Test Item (BT-TI) group showed 181% and 82.2% restoration of cell viability at 1 and 10 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. The UT-Med + BT-TI group showed 126.8% and 86.3% restoration of cell viability at 10 and 25 µg/mL, respectively with respect to the untreated group in human hepatoma cells (HepG2). Furthermore, 101.2% (at 10 µg/mL), 103.6% (at 10 µg/mL) and 135% (at 25 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 90%, 87.3% and 86.9% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 10 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 137% in the BT-Med + UT-TI group in human endometrial adenocarcinoma cells (Ishikawa) at 1 µg/mL compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 52.1%, 65.9% and 63.5% at 1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 157% and 58.9% at 0.1 and 10 µg/mL, respectively in the BT-Med + BT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 168% and 135.4% in the UT-Med + BT-TI group at 10 and 25 µg/mL, respectively; while, 137% at 10 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Serotonin level was significantly increased by 50.8% (at 63 µg/mL), 78.8% (at 63 µg/mL) and 52.7% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 265.5% (at 0.1 µg/mL) and 253.4% (at 1 µg/mL) in the UT-Med + BT-TI group; while 335.3% (at 0.1 µg/mL) in the BT-Med + BT-TI group compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the relevant bones, heart, liver, lungs and brain-related biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.</p>
Alan Joseph Balmer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.scitcentral.com/article.php?journal=43&article=778">http://www.scitcentral.com/article.php?journal=43&article=778</a>
SciTech Central Inc.
June 15, 2019
English
Journal Article
Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study
Organ Health
<p style="text-align:justify;">Multiple organ dysfunction syndrome or failure is one of the major concerns against healthcare services in order to maintain the normal function. The present study aimed to explore the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts, one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Ariadne Esmene Afaganis, Canada and was labeled as the Biofield Treated (BT) test formulation/media. The test formulation was tested for cell viability, and the data suggested that the test formulation was found safe and non-toxic against all the cell lines. Cytoprotective activity among the experimental groups showed a significant improved activity by 94.4% at 1 µg/mL in untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) group in human cardiac fibroblasts cells (HCF) cells, while 84.4% at 10 µg/mL in BT-Med + BT-TI groups in human hepatoma cells (HepG2), and 124% increased cytoprotective action at 1 µg/mL in UT-Med + BT-TI group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. ALP activity in MG-63 cells was significantly increased by 85.9% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 59.2% at 0.1 µg/mL in BT-Med + BT-TI groups as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 53% and 40.5% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 68.5%, 70.7%, and 16.8% at 0.1, 1, and 10 µg/mL respectively, and 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 33.5%, 63.2%, and 99.2% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by increased by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated group. Serotonin level was significantly increased by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 159.1% (at 50 µg/mL), 212.7% (at 1 µg/mL), and 278.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the present data concluded that the overall multiple organ health using various standard biomarkers in specific cell lines were significantly improved with respect to health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). Thus, it can be used as a complementary and alternative therapy approach against many multiple organ disorders such as coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Ariadne Esmene Afaganis, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
<a href="https://openaccesspub.org/jtrr/article/1131#idm1843080236">https://openaccesspub.org/jtrr/article/1131#idm1843080236</a>
Open Access Pub
Jul 13, 2019
English
Journal Article
10.14302/issn.2640-6403.jtrr-19-2946
An Alternative Approach for the Management of Bone Health: Role of Biofield Energy Healing Treated Vitamin D3
Nutraceuticals
<p style="text-align:justify;">The main aim of this experiment was to assess the impact of Consciousness Energy Healing-based vitamin D3 and DMEM medium on bone health parameters. The test items, were divided into two parts. One part of each sample received the Consciousness Energy Healing Treatment by Brian Anthony Weekes and those samples were labeled as the Biofield Energy Treated (BT) samples, while the other parts of each sample were denoted as the untreated test items (UT). Different parameters like ALP, collagen, and bone mineralization were performed to evaluate the bone strength and integrity in human bone osteosarcoma cells (MG-63). The test samples were found as safe in the tested concentrations by MTT cell viability assay. ALP was significantly increased by 19.49% and 63.49% in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively at 1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the ALP level was significantly elevated by 35.92% and 61.17% in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the UT-DMEM + UT-Test item group. Collagen was significantly increased by 53.75% and 42.43% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively at 1 µg/mL compared to the untreated group. Further, the collagen level was significantly increased by 46.54% and 122.61% at 50 and 100 µg/mL, respectively in the BT-DMEM + UT-Test item group compared to the untreated group. Additionally, the percent of bone mineralization was distinctly increased by 18.12%, 96.33%, and 150.85% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the untreated group. Further, the percentage of bone mineralization was significantly increased by 61.96 and 22.84% in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the untreated group. Overall, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an alternative nutraceutical supplement to combat vitamin D3 deficiency and fight against various bone related problems including rickets, low bone density, osteomalacia, bone and joint pain, bone fractures, osteoporosis, osteoma, osteogenesis imperfecta, Paget’s disease of bone, deformed bones, chondrodystrophia fetalis, stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.</p>
Brian Anthony Weekes, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=252&doi=10.11648/j.ajim.20180601.11">http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=252&doi=10.11648/j.ajim.20180601.11</a>
Science Publishing Group
10 January 2018
English
Journal Article
10.11648/j.ajim.20180601.11
Improved Structural and Functional Integrity of Bone Health Parameters After Treatment with Consciousness Energy Treated Vitamin D3
Nutraceuticals
<p style="text-align:justify;">The study objective was to investigate the effect of Consciousness Energy Healing-based vitamin D3 and DMEM medium on bone health. The test items (vitamin D3 and DMEM), were divided into two parts. One part of each sample was received the Biofield Energy Treatment by Debra Jane Schnitzer and those samples were denoted as the Biofield Energy Treated (BT) samples, while the other parts of each sample were referred as the untreated test items (UT). Parameters such as ALP, collagen, and bone mineralization were performed to evaluate the bone strength in human bone osteosarcoma cells (MG-63). The test samples were found as safe in the tested concentrations by MTT cell viability assay. ALP was significantly increased by 27.75%, 28.21%, and 60% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the UT-DMEM + UT-Test item group. Moreover, the ALP level was significantly raised by 11.17% and 74.57% in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively at 100 µg/mL compared to the UT-DMEM + UT-Test item group. Collagen was significantly increased by 54.53% and 115.01% in the UT-DMEM + BT-Test item and BT-DMEM + UT-Test item groups, respectively at 0.1 µg/mL compared to the untreated group. Further, the collagen level was significantly increased by 131.87% (at 1 µg/mL) and 179.77% (at 10 µg/mL) in the UT-DMEM + BT-Test item group compared to the untreated group. Apart from this, the percent of bone mineralization was distinctly increased by 75.94%, 125.79%, and 117.38% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 10 µg/mL compared to the untreated group. Additionally, the percentage of bone mineralization was significantly increased by 46.08%, 173.22%, and 171.17% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated group. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an alternative approach for nutraceutical supplement to combat vitamin D3 deficiency and able to fight against various bone-related disorders including rickets, low bone density, osteomalacia, bone and joint pain, bone fractures, osteoporosis, osteoma, osteogenesis imperfecta, Paget’s disease, deformed bones, chondrodystrophia fetalis, stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.</p>
Debra Jane Schnitzer, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=378&doi=10.11648/j.jfmhc.20170304.13">http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=378&doi=10.11648/j.jfmhc.20170304.13</a>
Science Publishing Group
11 January 2018
English
Journal Article
10.11648/j.jfmhc.20170304.13
Evaluation of Biofield Energy Treated Vitamin D3 on Bone Health Parameters in Human Bone Osteosarcoma Cells (MG-63)
Nutraceuticals
<p style="text-align:justify;">The study was aimed to evaluate the effect of Consciousness Energy Healing based vitamin D3 and DMEM medium on bone health parameters. The test items, were divided into two parts. One part of each sample received the Consciousness Energy Healing Treatment by Dezi Ann Koster and those samples were labeled as the Biofield Energy Treated (BT) samples, while the other parts of each sample were denoted as the untreated test items (UT). Different parameters were performed for the evaluation of bone health like ALP, collagen, and bone mineralization in human bone osteosarcoma cells (MG-63). The cell viability (MTT) data showed the test samples were found as safe in the tested concentrations. The level of ALP was significantly increased by 431.44% and 436.87% in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item, respectively at 1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the ALP level was significantly elevated by 163.34%, 44.91%, and 57.67% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated. Collagen was significantly increased by 56.58%, 84.95%, and 43.27% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 0.1 µg/mL compared to the untreated. Further, the collagen level was significantly increased by 21.27%, 47.26%, and 63.1% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 50 µg/mL compared to the untreated. Besides, the percent of bone mineralization was distinctly increased by 41.87% and 91.87% at 1 µg/mL in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item groups, respectively while, increased by 72.66% and 186.68% at 50 µg/mL in the UT-DMEM + BT-Test item and BT-DMEM + BT-Test item groups, respectively compared to the untreated. The percent of bone mineralization was distinctly increased by 101.21%, 57.76%, and 125.53% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item, respectively at 10 µg/mL compared to the untreated. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an excellent alternative nutraceutical supplement against various bone-related disorders including osteoporosis, low bone density, osteogenesis imperfecta, Paget’s disease, rickets, osteomalacia, deformed bones, autoimmune and inflammatory diseases, stress management and prevention, and anti-aging by improving overall health.</p>
Dezi Ann Koster, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=244&doi=10.11648/j.bmb.20180301.12">http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=244&doi=10.11648/j.bmb.20180301.12</a>
Science Publishing Group
09 February 2018
English
Journal Article
10.11648/j.bmb.20180301.12
Biological Significance of the Biofield Energy Treatment Based Test Formulation on Various Biomarkers Using Cell-Based Assays
Organ Health
<p style="text-align:justify;">The aim of the present study determined the impact of the Biofield Energy Treated test formulation using cell lines related with vital organs functioning. Different cells based assay were used based on the vital organs function of bones, heart, liver, lungs, and brain. The test formulation and cells media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Dimitrius Anagnos, USA and were labeled as the Biofield Energy Treated (BT) test formulation / media. The test formulation was tested against various activities using cell line assay in their specific medium (Med). The test formulation was tested for cell viability, and the results showed that the test formulation at tested concentrations was found non-toxic against all the cell line. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 25.6% (at 63.75 µg/mL), 46.7% (at 0.1 µg/mL), and 109.5% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 41.3%, 22.8%, and 34.8% at 63.75 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. However, cyto-protective activity in human hepatoma cells (HepG2) showed improved cell viability by 117.7% (at 0.1 µg/mL), 61.3% (at 25.5 µg/mL), and 104% (at 0.1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was significantly increased by 105.7% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 368% and 602% at 0.1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups respectively, as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 58.8% at 1 µg/mL in the UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 32.6% at 25 µg/mL, and improved cellular protection by 60.4% and 109.5% at 25 and 63.75 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 35.9% (at 10 µg/mL), 84.2% (at 25.5 µg/mL), and 87.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 35.2% (at 0.1 µg/mL), 35.2% (at 0.1 µg/mL), and 79.7% (at 1 µg/mL), in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased at 25 µg/mL by 30.6%, 107.7%, and 89.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased at 50 µg/mL by 156.1%, 158.7%, and 68.1% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, Biofield Energy treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Dimitrius Anagnos, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
<a href="https://www.ommegaonline.org/article-details/Biological-Significance-of-the-Biofield-Energy-Treatment-Based-Test-Formulation-on-Various-Biomarkers-Using-Cell-Based-Assays--/2520">https://www.ommegaonline.org/article-details/Biological-Significance-of-the-Biofield-Energy-Treatment-Based-Test-Formulation-on-Various-Biomarkers-Using-Cell-Based-Assays--/2520</a>
Ommega Publishers
July 27, 2019
English
Journal Article
10.15436/2377-1313.19.2520
Influence of Biofield Treated Vitamin D3 on Proliferation, Differentiation, and Maturation of Bone-Related Parameters in MG-63 Cell-Line
Nutraceuticals
<p style="text-align:justify;">The study was aimed to evaluate the effect of Consciousness Energy Healing-based vitamin D3 and DMEM medium on bone health parameters such as alkaline phosphatase (ALP), collagen, and bone mineralization in human bone osteosarcoma cells (MG-63). The test items (vitamin D3 and DMEM), were divided into two parts. One part of each sample was received the Biofield Energy Treatment by Dimitrius Anagnos and those samples were denoted as the Biofield Energy Treated (BT) samples, while the other parts of each sample were referred as the untreated test items (UT). The test samples were found as safe in the tested concentrations by MTT cell viability assay. The level of ALP was significantly increased by 74.86% in the BT-DMEM + BT-Test item and 40.17% in the UT-DMEM + BT-Test item group at 0.1 and 50 µg/mL, respectively compared to the UT-DMEM + UT-Test item group. Moreover, collagen level was significantly increased by 228.22%, 185.40%, and 256.69% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 0.1 µg/mL compared to the UT-DMEM + UT-Test item group. Further, the collagen level was significantly increased by 88.61% and 130.65% in the BT-DMEM + UT-Test item and BT-DMEM + BT-Test item groups, respectively at 1 µg/mL compared to the untreated group. Apart from this, the percent of bone mineralization was distinctly enhanced by 98.61%, 111.67%, and 68.26% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 0.1 µg/mL compared to the untreated group. Additionally, the percentage of bone mineralization was significantly increased by 83.3%, 99.52%, and 50.26% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively at 1 µg/mL compared to the untreated group. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an alternative approach for nutraceutical supplement to combat vitamin D3 deficiency and able to fight against various bone-related disorders including rickets, low bone density, osteomalacia, bone and joint pain, bone fractures, osteoporosis, osteoma, osteogenesis imperfecta, Paget’s disease, deformed bones, chondrodystrophia fetalis, stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.</p>
Dimitrius Anagnos, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=345&doi=10.11648/j.ijbecs.20180401.12" target="_blank" rel="noreferrer noopener">http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=345&doi=10.11648/j.ijbecs.20180401.12</a>
Science Publishing Group
08 February 2018
English
Journal Article
10.11648/j.ijbecs.20180401.12
Assessment of the Biofield Energy Healing Based Test Formulation on Human Organ Health Specific Biomarkers In Vitro Assays
Organ Health
<p style="text-align:justify;">Herbal based test formulations have been used in most of the healthcare settings since time immemorial. The present experimental cell line study was designed to evaluate the impact of the Biofield Energy Treatment on test formulation and different cell line mediums related with vital organs functioning. Cell lines that were specific to different organ systems were used in the study using standard protocols. The Test Item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Eileen Mary Meagher, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 56.8% (at 63.75µg/mL), 57.5% (at 63.75µg/mL), and 124.8% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group in Human Cardiac Fibroblasts cells (HCF) cells, while 83.2% (at 63.75µg/mL), 93.8% (at 63.75µg/mL), and 20.6% (at 10µg/mL) improved cellular protection of human Hepatoma cells (HepG2) cells in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 11.3% (at 25.5µg/mL), 82.7% (at 63.75µg/mL), and 113.9% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. MG-63 cells were used for estimation of ALP activity, which was highly increased by 59.8% (at 0.1µg/mL), 269.7% (at 0.1µg/mL), and 105.7% (at 0.1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Besides, Ishikawa cells showed maximum increased ALP activity by 94.8% at 10µg/mL in the BT-Med+UT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 48.8% (at 1µg/mL), 62.9% (at 10µg/mL), and 103% (at 1µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI group, and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Alanine Amino Transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75µg/mL by 74.9% and 84.9% in the BT-Med+UT-TI and BT-Med+BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 21.7% (at 25.5µg/mL), 83.2% (at 0.1µg/mL), and 40% (at 25.5µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 50.8% (at 63.75µg/mL), 35.9% (at 10µg/mL), and 49.9% (at 10µg/mL) in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the Relative Quantification (RQ) of Vitamin D Receptor (VDR) was significantly increased by 135.2%, 291.4%, and 248.3% at 50µg/mL in the UT-Med+BT-TI, BT-Med+UT-TI, and BT-Med+BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Eileen Mary Meagher, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Crimson Publishers
June 26, 2019
English
Journal Article
Impact of the Biofield Energy Healing Based Test Formulation on Various Health Biomarkers Using Cell-Based Assays
Organ Health
<p style="text-align:justify;">Various complementary approaches have been used against multiple organ dysfunction syndrome (MODS), which is the major contributor in high mortality among the healthcare centers. The aim of the present study was to determine the impact of the Biofield Energy Treatment on test formulation and different cell line medium related with vital organs functioning. Different organ based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Elizabeth Patric, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 84.9% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 308.1% at 0.1 µg/mL in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 166.8%, 266.4%, and 153.3% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.</p>
Elizabeth Patric, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana
Annex Publishers
2019
English
Journal Article
Effect of Biofield Energized Vitamin D3 on Bone Health in MG-63 Cell-Line
Nutraceuticals
<p style="text-align:justify;">The objective of current research work was to evaluate the potential of Consciousness Energy Healing-based vitamin D3 and DMEM medium on bone health parameters such as alkaline phosphatase (ALP), collagen, and bone mineralization in human bone osteosarcoma cells (MG-63). The test items like vitamin D3 and DMEM were divided into two parts. One part of each sample was received the Biofield Energy Treatment by Faith Ann Pyka and those samples were denoted as the Biofield Energy Treated (BT) samples, while the other parts of each sample were referred as the untreated test items (UT). The MTT cell viability assay revealed that the test samples were found as safe in the tested concentrations. The level of ALP was significantly increased by 191.45% in the BT-DMEM + UT-Test item (UT-TI) group at 1 µg/mL compared to the UT-DMEM + UT-TI group. Moreover, ALP level was significantly increased by 144.89% and 226.75% in the UT-DMEM + BT-TI and BT-DMEM + BT-TI groups, respectively at 50 µg/mL compared to the untreated group. Further, collagen level was significantly increased by 98.15%, 80.54%, and 49.98% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI groups, respectively at 10 µg/mL compared to the untreated group. Additionally, at 50 µg/mL level of collagen was significantly increased by 129.73%, 189.16%, and 94.60% in the UT-DMEM + BT-Test item, BT-DMEM + UT-Test item, and BT-DMEM + BT-Test item groups, respectively with respect to the untreated group. Apart from this, the percent of bone mineralization was distinctly enhanced by 283.74%, 27.91%, and 118.02% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI groups, respectively at 50 µg/mL compared to the untreated group. Moreover, the percentage of bone mineralization was significantly increased by 265.92%, 231.82%, and 158.2% in the UT-DMEM + BT-TI, BT-DMEM + UT-TI, and BT-DMEM + BT-TI groups, respectively at 100 µg/mL compared to the untreated group. Altogether, the Biofield Energy Treated vitamin D3 was significantly improved the bone health parameters and it could be an alternative approach for nutraceutical supplement to combat vitamin D3 deficiency and able to fight against various bone-related disorders including rickets, low bone density, osteomalacia, bone and joint pain, bone fractures, osteoporosis, osteoma, osteogenesis imperfecta, Paget’s disease, deformed bones, chondrodystrophia fetalis, stress management and prevention, autoimmune and inflammatory diseases, and anti-aging by improving overall health.</p>
Faith Ann Pyka, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Sambhu Charan Mondal, Snehasis Jana
<a href="http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=219&doi=10.11648/j.ajbio.20180601.12">http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=219&doi=10.11648/j.ajbio.20180601.12</a>
Science Publishing Group
March 07, 2018
English
Journal Article
10.11648/j.ajbio.20180601.12